Psychedelics Therapy

Canadian magic mushrooms and truffles producer Red Light Holland Corp. (OTC: TRUFF)’s wholly-owned subsidiary, health tech firm Radix Motion Inc., has received an International Preliminary Report on Patentability for its patent application on 3D movement data usage in...

Biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed four new U.S. Patent Cooperation Treaty (PCT) applications aiming to convert five provisional patent applications.  These new filings bring the total number of PCT conversion filings completed by the company to 10. They “...

The Beckley Foundation and its founder and long-time psychedelics researcher Amanda Feilding announced a new research program involving a pioneering study with King's College London and UCL on the effects of full dose LSD as well as a breakthrough study with the University...

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands.  CEO Christopher J. Moreau said the company is thrilled to initiate...

Psychedelics biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) reported its business update and fiscal results for the second quarter ended September 30, 2022. Reunion’s president and CEO Greg Mayes stated that the company has consolidated as an independent company and is “well...

Elon Musk continues touting the benefits of psychedelics, from his live interview at CodeCon2021 to his most recent tweets endorsing those working towards developing these substances for better therapeutic effects and even revisiting his own experience with them. Tesla (NASDAQ:...

Clinical-stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) reported its third quarter financial results and operational highlights for the period ended September 30, 2022. Numbers show total cash was over $2.6 million (CA$3.5 million), compared to $3.47...

Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and business developments. Numbers on 30 September 2022 show: Cash and cash equivalents totaled $...

Mental health company Revitalist Lifestyle and Wellness Ltd. (OTCQB: RVLWF) is consolidating its presence in the expanding global market of plant-based psychedelic medicines and additional enhancing products with the release of a novel supplement product line called Vital+. Formulated to...

Democratic Assemblymember Linda Rosenthal's 2021 psychedelics bill was intended to delist psilocybin and psilocin as Schedule I substances. Nonetheless, on October 3, 2022, that same bill with additional stipulations broadening legal protection of adults possessing and using several...

(Part two of a four-part series, see part one here) Dr. Ben Sessa, cofounder and head of psychedelic medicine at Awakn Life Sciences (OTC: AWKNF) explained that scientific evidence shows ketamine creates neurogenesis: “You actually have growth of nervous tissue. You can...

(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public discussion and reform. Each compound is proven to have specific characteristics,...

Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder. Besides...

Optimi Health (OTCQX: OPTHF) has released an operational update on its planned year of commercialization, including the launch of psychedelics catalog. Optimi is licensed by Health Canada as a producer and supplier of natural GMP psilocybin and synthetic psychedelic substances....

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural psilocybin and other psychedelic substances, announced that it has entered into its first international psilocybin supply agreement with Promises...